|
Date
|
Update
|
|
08 June 2017
|
Committee meeting: 2 |
|
31 March 2017
|
The second committee discussion of palbociclib in combination with an aromatase inhibitor for previously untreated metastatic, hormone receptor-positive, HER2-negative breast cancer [ID915] will be held on 8 June 2017 at NICE London Offices, Prince of Wales Suite 10 Spring Gardens SW1A 2BU. |
|
29 March 2017
|
Following communication with the company, we have decided to postpone the second committee meeting to discuss palbociclib in combination with an aromatase inhibitor for previously untreated metastatic, hormone receptor-positive, HER2-negative breast cancer [ID915]. This is to allow the company to submit an updated evidence package including more data from the PALOMA-1 study.
The discussion of this topic on 06 April is therefore cancelled. We will update you when we have a new date for the committee discussion.
|
|
03 February 2017 - 24 February 2017
|
Appraisal consultation |
|
11 January 2017
|
Committee meeting: 1 |
|
01 August 2016
|
Invitation to participate |
|
21 June 2016
|
Draft scope documents |
|
13 May 2016
|
Referral |